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Objective: This research aims to validate the method for rifampicin analysis in plasma by using High-Performance Liquid Chromatography (HPLC) 
that can be used to study the bioequivalence of a generic tablet of rifampicin 450 mg “X” marketed in Indonesia.  
Methods: Bioequivalence test was analysed using HPLC equipped with UV-Vis detector at 377 nm. The mobile phase used was acetonitrile-
phosphate buffer pH 6.8 (45:55) delivered at a flow rate of 1.5 ml/min. Bioequivalence test was conducted on a limited number of subjects (n=8). 
The subjects were divided into two groups randomly. The pharmacokinetic profiles of the test tablet and reference tablet were statistically 
calculated using SPSS program to see the test tablet and reference tablet were bioequivalence or not. 
Results: The developed HPLC method for rifampicin analysis in plasma was sufficiently valid based on the International Conference on 
Harmonization (ICH) and European Medicines Agency (EMA) guideline, with precision and accuracy values were % Relative Standard Deviation (% 
RSD = 1.40–13.04) and % Recovery (86.24–102.13), respectively. Meanwhile, the method was linear over studied concentration (0.05 to 10.26 
µg/ml) with a coefficient of determination (R2
Conclusion: The test rifampicin tablet that was, the generic tablet “X” was bioequivalence toward the reference rifampicin tablet “Rimactan”.  
) = 0.9984. The method also had good stability and sensitivity. The result of statistical calculation 
showed that the generic rifampicin tablet X was bioequivalence toward the reference tablet Rimactan 450 mg.  
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Tuberculosis (TB) is an infectious disease, ranks as the second killer 
after human immunodeficiency virus (HIV) worldwide. In 2012, there 
were 8.6 million new TB cases and 1.3 million TB deaths reported by 
WHO. In Indonesia, the prevalence of TB was 257 per 100.000 
people in 2013. TB is caused by the bacillus Mycobacterium 
tuberculosis. Rifampicin is a macrocyclic antibiotic derived from 
Streptomyces mediterraneil used as the first line anti-TB drug 
together with Isoniazid (INH), Ethambutol, and Pyrazinamide [1, 2, 
3]. Rifampicin acts as anti-TB by inhibiting the DNA-dependent RNA 
polymerase of the bacterial cells [4].  
As a consequence of the high prevalence of TB is high demand for TB 
drug. To overcome this problem, pharmaceutical industries produce a 
copy of rifampicin drug. Rifampicin is available in some oral dosage 
forms and strength: 75, 150, 300, 450 mg, and 600 mg capsule or 
tablet [5]. After the administration of the 600 mg dosage form, the 
maximum plasma concentration (Cmax) of rifampicin is targeted to be 
8-24 μg/ml. The lower or higher value of Cmax will influence the 
expected pharmacological effect [6]. Since the bioavailability of the 
drug is highly affected by the formulation of the dosage form, so it is 
important to establish bioavailability and bioequivalence study to 
every new copy of rifampicin drug. Furthermore, a different 
formulation of marketing rifampicin dosage forms itself delivered 
variability in the bioavailability [7]. Therefore, it is necessary to 
develop accurate, sensitive, reproducible, and simple analytical 
method to support the study. 
Several analytical methods for the determination of rifampicin in 
plasma are already reported, including HPTLC [8], LC-MS [9], LC-
MS/MS [10, 11] and HPLC or UPLC-UV method [12, 13]. Those 
methods have some drawbacks so that those unsuitable and cannot 
be directly implemented in our Advanced Pharmaceuticals Science 
Laboratory as part of bioavailability and bioequivalence testing 
service provided. The previous method was considered expensive, 
complicated, and time-consuming. So, we developed an accurate, 
precise, cheaper, and simpler HPLC-UV method to analyze rifampicin 
in human plasma. This method involves deproteination and liquid-
liquid extraction prior to HPLC analysis with C18 column and was 
validated as per the European Medicines Agency (EMA) guideline on 
Bioanalytical method validation [14]. 
 
 
Fig. 1: Chemical structure of rifampicin 
 
MATERIALS AND METHODS 
Chemicals and materials 
Rifampicin standard (≥ 9 0.0% from Sigma-Aldrich (Dorset, UK), 
Rifampicin generic tablet “X” 450 mg from Indonesia, Rimactan Tablet 
450 mg from Novartis. Triethanolamine, phosphoric acid and glacial 
acetic acid were obtained from Merck (Darmstadt, Germany). Methanol 
and acetonitrile HPLC grade were purchased from Merck (Darmstadt, 
Germany). Human plasma was from the Indonesian Red Cross.  
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HPLC was equipped with UV-Vis L-2420, pump L-2130 and 
Lachrom C18 column (250 X 4.6 mm; 5 µm) from Hitachi (Japan). 
Refrigerated centrifuge (Dynamica Velocity 18R, UK), vortex 
thermolyne 16700 mixer (USA), semi microbalance (OHAUS 
EX225D, USA), deep freezer (NUAIRE NU-9483 E, USA), and 
glassware. 
Suitability of HPLC system for rifampicin analysis 
An amount of 20 µl of rifampicin standard solution (2.5 µg/ml) 
was injected into HPLC (operated as condition in table 1) for eight 
times. The chromatograms were evaluated and calculated 
percentage relative standard deviation (% RSD) of retention time 
(RT) and resolution factor (Rs), tailing factor and plate theoretic 
number (N). The system was suitable for rifampicin analysis if all 
parameters met to the acceptance criteria as in ICH and EMA 
guidelines [15, 16]. 
  
Table 1: Operational condition of HPLC used for rifampicin analysis in plasma (refers to the USP 30 Pharmacopeia with slight 
modification [17]) 
Stationary phase C18 (25 cm, 0.4 cm i.d., 0.5 µm particle sizes) 
Mobile Phase A: Acetonitrile 
B: Phosphate buffer solution (pH 6.8) 
Composition A: B (45:55) 
Flow Rate 1.5 ml/min 
Detector UV spectrophotometer at 377 nm 
Volume of injection 20 µl 
  
Spiked human plasma preparation  
As much as 750 µl of plasma was added by rifampicin standard as 
needed and 1 ml of acetonitrile, then centrifuged in 10.000-12.000 
rpm for 10 min. The supernatant was taken and repeated the 
extraction process once again. The acetonitrile phase was collected 
and evaporated until dryness. The precipitate was re-suspended in 
the mobile phase (1 ml) and filtered using 0.45 µm filter syringe 
prior injected into the HPLC. 
Method validation 
Method validation was needed to assure that the developed method 
was capable for producing the reliable and consistent result, as well 
as fits to its intended purposes. In this study, method validation was 
conducted by determining several parameters including selectivity, 
carry over, linearity, sensitivity, precision, accuracy, dilution 
integrity, stability and ruggedness which were worked in acceptance 
of ICH and EMA guidelines [18, 14, 19]. 
Selectivity 
Selectivity of method was proven by comparing the chromatogram 
of the mobile phase, plasma blank, and spiked plasma with standard 
rifampicin. If there was no signal at the retention time of rifampicin, 
it can be concluded that the method was selective. The selectivity 
was also calculated by calculating Resolution Factor (Rs). 
Acceptance criteria for selectivity parameter was Rs>2 [20]. 
Carry-over 
Carryover was conducted by injecting the blank sample after 
injecting the standard solution at the high concentration (more than 
the upper limit of quantification). Acceptance criteria: Carryover in 
the blank sample following the high concentration standard should 
not be greater than 20% of the lower limit of quantification (LLOQ) 
and 5% of the internal standard [21, 14]. 
Linearity of the calibration curve 
Calibration curve was prepared by adding a series concentration of 
rifampicin standards into blank plasma until having concentration of 
0.05; 0.10; 0.50; 1.00; 2.50; 5.00; 7.50; and 10.00 μg/ml. The peak area 
of each concentration was then plotted on their concentration. A linear 
regression curve was made in formula Y = BX+A; X was the 
concentration of rifampicin and Y was peak area. Coefficient of 
correlation (R) and coefficient of determination (R2) was calculated 
and evaluated according to the acceptance criteria including R-value ≥ 
0.999 and R2
Sensitivity 
 value ≥ 0.997 [20, 21]. Moreover, it had to meet the 
acceptance criteria of EMA, namely the back-calculated concentrations 
of the calibration standards should be within±15% of the nominal 
value, except for the LLOQ for which it should be within±20%. At least 
75% of the calibration standards, with a minimum of six calibration 
standard levels, must fulfill this criterion. LLOQ sample should be at 
least 5 times the signal a blank sample [14]. 
Sensitivity was determined as the limit of determination (LOD) and 
limit of Quantification (LOQ). LOD was defined as the minimum 
concentration of rifampicin that can be detected properly by the 
system of analysis, whilst LOQ was defined as the minimum 
concentration of rifampicin that can be quantified properly by the 
system of analysis. LOD and LOQ was measured with the formula:  
LOD = 3 SD
B
 
LOQ = 10 SD
B
 
SD: standard deviation of intercept or standard deviation of the 
lowest concentration of standard rifampicin detected in 10 triplicate 
analysis 
B: the slope of the calibration curve 
Accuracy 
Accuracy was carried out by measuring the percent of recovery or a 
percent of the nominal value. Accuracy was measured by adding a 
number of rifampicin standard in plasma and then analysed. 
Accuracy should be evaluated to the values of the QC samples 
obtained within a single run (the within-run accuracy) and in 
different runs (the between-run accuracy) [14, 22, 23]. 
Within-run accuracy 
Within-run accuracy was carried out by analysing in a single-run of 
5 samples per concentration at 4 different concentrations 
representing low, middle, and high concentrations. The mean 
calculated concentration should be within 15%, except for the low 
concentration should be within 20% of the nominal value [14].  
Between-run accuracy 
Between-run accuracy was conducted at least on 4 different 
concentrations (representing low, middle, and high concentrations) 
and analysed on at least two different days. The mean of calculated 
concentration should be within 15%, except for the low 
concentration which should be within 20% of the nominal value 
[14]. 
Precision  
Precision parameters were expressed as the percentage relative 
standard deviation (% RSD) of calculated concentration. There were 
two precision parameters, namely within-run precision and 
between-run precision [14].  
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Within-run precision was conducted at least 5 samples per 
concentrations (representing low, middle, and high concentrations) 
in a single run. For within-run precision, % RSD value should not 
exceed 15% for the middle and high concentration, except for the 
LLOQ which should not exceed 20%. 
Between-run precision 
Between-run precision was conducted using the same concentration 
as in the determination of within-run precision. However, it was 
analysed on two different days. % RSD value for between-run 
precision should not exceed 15% for the QC samples, except for the 
LLOQ which should not exceed 20%. 
Dilution integrity 
This parameter was to evaluate the effect of dilution on the precision 
and accuracy parameters. It was carried out by diluting 15 µg/ml of 
standard solution in 2 and 10 times dilution factors. Acceptance 
criteria: %RSD of accuracy and precision should be within the set 
criteria or±15% [14]. 
Stability 
Stability was measured to find out the effects of several treatments 
during analysis on the result of the measurement. In this case, 
stability test was measured during storage at the room 
temperature,-20 °C, and-80 °C, as well as during delivery from the 
location of sample collection (UGM Hospital) to the laboratory. The 
acceptance criteria: the mean of concentration at each assessment 
should be within±15% of the nominal concentration [14]. 
Ruggedness  
Ruggedness was calculated by comparing the result of the 
determination of spiked plasma in the concentration of 5 µg/ml, 
which was conducted by the researcher, and the analysis result from 
another laboratory. After then, a statistical calculation was 
conducted by using the t-test. If p>0.05, the average difference from 
both results was not significant. 
Bioequivalence study of rifampicin 
Ethical clearance 
This research was carried out under the Declaration of Helsinki [23], 
Good Clinical Practice [24] and Good Laboratory Practice [25]. The 
protocol of research, informed consent of the patient, and guidance 
of calling participants must be reviewed and got the consent of 
ethical clearance from an ethics commission (medical and health 
research ethics committee) of Faculty of Medicine, Universitas 
Gadjah Mada before being applied in this research. The number of 
ethical clearance for doing this research is KE/FK/602/EC/2015. 
Study design 
The study design was a randomized cross over using 8 (eight) 
subjects. The administration of the test drugs between stage 1 and 
stage 2 on the subjects was carried out in a washout period for 1 w. 
During this period, the test subjects must not consume any drugs, 
including herbs [26, 27]. 
Inclusion and exclusion criteria 
According to the guideline of good clinical practice, the inclusion and 
exclusion criteria had been set before selecting subjects. Inclusion 
criteria were healthy volunteers, male or female, 18-55 y old, not a 
cigarette smoker, not consuming any drugs in a week before the test. 
Subjects should be having normal weight with body mass index 
(BMI) around 18-25. Health condition should be proved by a clinical 
laboratory test. Female subjects were not pregnant women and 
proved by the pregnancy test. Exclusion criteria were women who 
are pregnant, breastfeeding and consuming contraception pills. 
People were having contraindication and allergy with rifampicin, 
smoking and drinking alcohol, having a history of drug and alcohol 
addiction as well cannot be as subject [26, 27]. 
Before starting this research, subjects were given an explanation of 
the informed consent and opportunity to ask for as much as an 
explanation. After then, the subjects were asked to sign the informed 
consent of joining the research [14]. Volunteers who were willing to 
participate as the subjects should follow the health examination, 
including laboratory test of urine and blood as well as liver and 
kidney function. Urine examination was carried out to examine the 
reduction of glucose, urobilin, bilirubin, albumin, and sediment. 
Blood examination included hemoglobin, hematocrit, the amount 
and types of leukocytes, erythrocyte, and total protein. Examination 
of liver functional covered bilirubin (total, direct and indirect), 
alanine transaminase (ALT) and aspartate transaminase (AST), 
while kidney examination included proteinuria, serum urea and 
serum creatinine. Additionally, the subjects were not allowed to take 
any medication one week before and during this pharmacokinetic 
research.  
Conditioning subject and drug admission  
The night before the test, the subjects were asked to come to UGM 
hospital no later than 7:00 p. m. for staying overnight. The night 
before the bioequivalence test was conducted, each subject was 
asked to start fasting at 9:00 p. m.; drinking water was allowed in ad 
libitum. Subjects were also not allowed to consume any drinks 
containing alcohol, caffeine, tea, and chocolate at least 24 h before 
the administration of rifampicin until the test I complete (the latest 
blood sampling was conducted).  
At 7:00 a. m., the blood sample (7 ml) was taken as a blank, followed by 
drug administration of 450 mg per dosage with 250 ml water. And then, 
the blood sample was serially taken at 0 and 30 min, and 1; 1.5; 2; 2.5; 3; 
3.5; 4; 6, 8; 10; 12; 18 and 24 h after consuming the drug using the 
vacutainer that contained heparin. Plasma was separated and stored in a 
frozen temperature (-20 °C) in a glass tube in an upright state and 
wrapped in aluminum (to prevent contact with rubber caps and 
photodecomposition) until the analysis was carried out. 
The subjects were given breakfast with standardized composition 4 
h after drug administration. They were allowed to drink water 
anytime except 1 hour before and 2 h after drug administration. 
They were given lunch and dinner 8 h and 12 h after drug 
administration. They were also allowed to consume other foods of 
which composition met the standard and did not interact with drugs 
or disturb the normal function of gastrointestinal, liver, or kidney. 
Besides food, all-day physical activities have also been standardized 
to reduce the variability among subjects that may occur, such as 
motility and blood flow in the gastrointestinal tract. During the 
research, every complaint regarding side effects of the drug will get 
proper attention and treatment from the medical person in charge. 
Clinical side effects of rifampicin that need to be taken into account 
were nausea, vomiting, anorexia, diarrhea, influenza syndrome, 
respiratory disorder, collapse and shock, hemolytic anemia, acute 
renal failure, urticaria, and impaired liver function. 
Bioanalysis of rifampicin in plasma 
Determination of rifampicin in plasma was carried out by measuring 
parent compound using HPLC (High-Performance Liquid 
Chromatography) based on the modified Pharmacopeia USP 30 method 
[17]. Determination of rifampicin in plasma samples was done using a 
validated bioanalytical method, as in the method above and followed by 
measuring rifampicin concentration using calibration curve. 
Parameters of pharmacokinetics that should be evaluated 
The relationship between the area under the curve (AUC) of 
chromatograms and the sampling time used to assess the amount 
and speed of absorption, distribution and elimination. Bioavailability 
parameters of the blood sample used for analysis included the area 
under curve toward the duration from 0 to the last time of sampling 
(AUCt) and calculated using the trapezoidal method; AUC from time 
0 until infinite time (AUC∞);  maximum concentration of rifampicin 
in observed plasma (Cmax); time after drug administration at which 
maximum concentration occured (tmax) and half-time of drug 
elimination (t1/2). 
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Pharmacokinetic analysis of rifampicin was carried out using non-
compartmental model. Cmaks and tmax values were taken from the real 
values of drug level in plasma toward the time on each subject. AUC, first-
order rate constant for elimination of drug from the central 
compartment of the pharmacokinetic model (kel), t1/2, mean of residence 
time (MRT), apparent volume of distribution at steady state (Vd(ss)) and 
clearance (Cl) were calculated using PK’s function software (under 
Microsoft Excel). Level-dependent data were AUC and Cmax
A. Ratio of the average geometric value of AUC
, which were 
transformed into logarithmic (ln) form first to find out the normality of 
data distribution. Pharmacokinetics parameter calculated from both 
drugs (rifampicin tablet test and rifampicin tablet reference) was 
analysed based on variance (ANOVA) with a confidence level of 90% [24, 
25]. The statistics software used was SPSS version 10.00.  
Bioequivalence parameter 
Test drug (test = T) and comparative drug (reference = R) were said 
to be bioequivalence if:  
T/AUCR
B. Ratio of the average geometric value of (C
 = 1.00, with 
90% CI = 80.00-125.00%. 
max)T/(Cmax)R
RESULTS AND DISCUSSION 
 = 1.00, 
with 90% CI = 75.00–130.00% 
System suitability test 
Using HPLC operational condition as in table 1, the system suitability 
test was conducted using standard rifampicin. The result of the 
system suitability test was summarized in table 2. 
Based on the result in table 2, it can be seen that HPLC condition was 
suitable for rifampicin analysis since it fulfilled the acceptance 
criteria [16], namely % RSD of retention time and area of 0.90% and 
1.62% (less than 2%), resolution factor of 4.23±0.73 (more than 2), 
tailing factor 1.13±0.01 (less than 1.5) and theoretical plate number 
of 7025±64 (more than 2000). Using an HPLC system, then the 
method of rifampicin analysis in plasma was validated.  
Selectivity 
The following fig. 2 revealed chromatograms of the mobile phase, 
plasma blank without rifampicin, and spiked plasma with 
rifampicin. There was no peak that had the same retention time as 
rifampicin, in both blank chromatogram (B) and mobile phase 
chromatogram (A). Thus, it can be concluded that the method was 
selective, which was able to distinguish the analytic signal from an 
interference signal. 
  
Table 2: System suitability test of rifampicin analysis using HPLC 
Parameter Replication Mean %RSD Acceptance criteria 
1 2 3 4 5 6 
Retention time (min) 4.37 4.32 4.32 4.29 4.29 4.27 4.32 0.90 RSD ≤ 2% 
Area 4537 46414 44979 44438 45386 44813 45321 1.62 RSD ≤ 2% 
Tailing factor (Tf) 1.13 1.12 1.13 1.13 1.12 1.15 1.13 0.09 <1.5 
Theoretical plate number (N) 7112 7065 7061 6992 6956 6962 7025 0.91 ≥ 2000 
Capacity factor (k’) 435.67 433.67 431.00 428.33 427.67 426.33 430.45 0.85 - 
Resolution factor (Rs) 5.70 3.97 3.86 4.03 3.92 3.87 4.23 17.17 ≥ 2 
 
 
Fig. 2: Chromatograms of mobile phase (a); plasma blank (b); standard solution of rifampicin (c); plasma spiked with 10 µg/ml of 
rifampicin (d); plasma sample of subject (f) 
 
Table 3: Calibration curve of rifampicin analysis 
Concentration of rifampicin (µg/ml) Area % error 
0.051 1031 19.06 
0.103 1761 20.01 
0.518 8394 14.38 
1.028 18704 2.91 
2.565 47210 1.13 
5.129 98454 3.40 
7.694 147358 3.26 
10.259 185366 2.54 
Note: each concentration was injected into the HPLC system in triplicate analysis 
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Fig. 3: Calibration curve of rifampicin in plasma matrix 
 
Calibration curve and sensitivity 
The calibration curve, the relationship between standard 
concentration and chromatogram area has made, and the result was 
represented in table 3 below. 
The regression equation of calibration curve (fig. 3) was found to be 
Y = 18517.8923 X+230.70; with r = 0.9992 and R2
Sensitivity of the analytical method was evaluated by measuring 
limit of detection (LOD) and limit of quantification (LOQ) using 
formula stated in the method section. SD was the standard deviation 
of the chromatogram area of spiked plasma with rifampicin in low 
concentration (0.05 µg/ml) in 8 replicate analysis. B was the 
intercept value of the calibration curve (230.70). The SD obtained 
from this research was 166.582. Therefore, LOD and LOQ values 
were 0.015 and 0.077 µg/ml respectively. The sensitivity of this 
method was better than sensitivity found in other methods [29] 
which had LOD and LOQ values were 0.110 and 0.332 µg/ml, 
respectively.  = 0.998. Linear 
regression equation met the requirement of the valid method since 
the calculated concentration has % error within 15% [14], except for 
low concentration in the value of 20%. More than 75% of the 
calculated concentration have % error of less than 15%. Using this 
linear regression equation, rifampicin in plasma can be calculated 
after the chromatogram area was obtained. 
Carryover test 
There was no rifampicin peak in the chromatogram of mobile phase 
that it injected after injection of rifampicin in high concentration. 
Accuracy and precision 
Accuracy parameter was expressed as % recovery and carried out at 
4 level concentrations in 5 replications per concentration (0.050; 
0.150; 5.000; 8.000 µg/ml). A detailed recovery data generated for 
the assay validation was represented in table 4 and table 5 below. 
 
Table 4: Within-run accuracy 
Actual concentration (µg (µg/ml) Calculated concentration (µg/ml) Recovery (%) 
0.052 0.048 91.95±7.54 
0.155 0.1334 86.24±13.04 
5.129 5.131 100.03±2.56 
8.207 8.382 102.13±3.25 
Note: Recovery was represented as mean±RSD in 5 replicates for each concentration 
 
Table 5: Between-run accuracy 
Actual concentration (µg/ml) Recovery per Day (%) Recovery between-run (%) 
Day-1 Day-2 Day-3 
0.052 91.95 88.55 111.46 97.32±10.37 
0.155 86.24 105.00 87.59 92.94±9.19 
5.129 100.03 97.34 96.94 98.10±1.40 
8.207 102.13 91.68 98.16 97.32±4.43 
Note: Between-run accuracy was expressed as recovery (%) and represented as mean±RSD of 4 level concentration in 5 replicate determinations 
per concentration in 3 different days. 
 
Based on table 4 and table 5, it showed that the analytical method 
tested met the criteria of within-run accuracy since its recovery was 
about 86.24–102.13% (acceptance criteria 85–115%) and all RSDs 
were less than 15%. Between-run accuracy also met the criteria 
since its recovery from three different days was between 86.24–
111.46% and all RSDs were less than 15%. Both within-run and 
between-run precisions also met the criteria because RSD of within 
run was 2.56–13.04 % (acceptance criteria within 15%), and RSD 
between-run was 1.40–10.37 % (acceptance criteria within 15%). 
Thus, the proposed method of analysis met the criteria of the valid 
analytical method and can be used for regular analysis. The overall 
recovery and precision parameters were within the acceptability 
criteria of Bioanalysis validation procedure from the European 
Medicines Agency (EMA) and the Food and Drug Administration 
(FDA) guideline [14, 29]. 
Dilution integrity 
Dilution integrity was evaluated to ensure that there was no 
significant effect of the dilution process in determining rifampicin 
level in plasma [14]. In this research, the effect of dilution has been 
evaluated using 15 µg/ml of standard solution diluted twice and ten 
times. The result was summarized in table 6. It can be concluded 
that there was no significant effect of the dilution process on the 
result generated from this method. 
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Table 6: Result of dilution integrity test 
Standard concentration (µg/ml) Dilution factor Actual concentration (µg/ml) Calculated concentration* (µg/ml) Significance** 
15.39 0 x 15.39 15.85±9.28 p = 0.428 
2 x 7.70 7.74±3.59 
10 x 1.54 1.49±2.51 
Note: *Data was represented as mean±% RSD obtained from 5 replicate the analysis for each dilution factor, **p (0.428)>0.05; there were no 
significant differences between actual and calculated concentration 
 
Stability 
Stability test has also been performed in this research. The result 
can be seen in table 7. Stability test was essential to ensure that the 
analyte was not broken since it was taken up to the time of analysis 
[14]. Based on table 7, it can be concluded that the analytical method 
was stable since the mean calculated concentration at each level and 
each condition should be within±15% of actual concentration or its 
recovery was about 85–115 %. 
Ruggedness 
Ruggedness testing has also been carried out in this research. By 
comparing the analysis result conducted by the researcher 
toward the analysis result done by other laboratories (in this 
case was the Indonesian Agency of Drug and Food Monitoring or 
BPOM in Indonesia), it showed that there were any significant 
differences among both results, and it still met the criteria of a 
valid method. 
 
Table 7: Result of stability test 
Actual concentration (µg/ml) Recovery after treatment* 
0h, 25 °C 2h, 25 °C 4h, 25 °C 2d,-20 °C 30d,-80 °C 
0.155 100% 103.66 % 103.62 % 93.75 % 92.20 % 
8.207 100% 93.80% 102.78% 97.52 % 106.72 % 




Fig. 4: Chromatograms of blank plasma (A) and sample of the subject in 3 h after consuming test drug (B) 
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Table 8: Result of ruggedness test 
Calculated concentration (µg/ml) Significance  Conclusion 
UGM laboratory BPOM laboratory 
4.59 5.01 p = 0.049 There was no significant difference in the analysis results in both 
UGM and BPOM Laboratory. 4.59 4.80 
4.62 4.89 
4.68 4.70 
Based on the result of the validation method, it can be concluded that this developed method can be used to analyse rifampicin concentration in the 
blood plasma for bioequivalence study. 
 
Results of bioequivalence study 
To ensure that there was no interference of endogen matrix found in 
plasma sample or metabolite of rifampicin, it was necessary to 
evaluate chromatograms of blank plasma and plasma of subject after 
consuming rifampicin tablet [28, 30]. Fig. 4 below showed 
chromatogram of plasma samples from a subject that has given 
rifampicin orally (B) compared to chromatogram from blank plasma 
(A). Based on fig. 4, there was no metabolite or other endogenous 
substance that interfering analysis, so that the method was suitable 
to be used in bioequivalence study. 
Procedure of bioequivalence analysis carried out in this research has 
been given permission by the Medical and Health Research Ethnics 
Committee (MHREC), Faculty of Medicine, Gadjah Mada University-
DR. Sardjito Hospital with number: KE/FK/602/EC/2015. 
Based on the analysis result of rifampicin level in plasma (Cp) 
obtained from subjects (n=8) that have met the criteria as a good 
subject for bioequivalence test, the average pharmacokinetic 
parameters of rifampicin generic tablet “X” and rifampicin reference 
tablet “R” can be calculated. Fig. 5 below was the pharmacokinetic 
profile of the two tablets. 
  
 
Fig. 5: Pharmacokinetics profile of rifampicin generic Tablet “X” and reference tablet “R” 
 
In table 9, the detail of each pharmacokinetic parameter was 
presented. In bioequivalence test, pharmacokinetic parameters that 
should be calculated statistically were AUC, Cmax and tmax. However, 
the most relevant parameters for bioequivalence test were AUC and 
Cmax,
  
. AUC can be trusted most for describing absorption (the 
number of bioavailable drugs) [23, 24]. 
Table 9: The pharmacokinetics parameters of rifampicin 
Pharmacokinetics parameter Generic * Reference 
kel 0.21±0.01  (per hour) 0.21±0.02 
t1/2 3.30±0.14 (h) 3.47±0.29 
AUCt 29.16±4.05  (µg*h*/ml) 27.20±3.98 
AUC∞ (µg*h/ml) 29.41±4.07 27.49±4.01 
tmax 1.25±0.13  (h) 1.31±0.13 
Cmax 5.81±0.88  (µg/ml) 5.04±0.56 
*Note: all pharmacokinetic parameters were expressed as mean±SEM obtained from 8 subjects, SEM was the standard error of the mean, The result 
of the statistical test using variance analysis (ANOVA) for two-way cross design considering the source of variations in drug products and the period 
of drug administration was provided in table 10. 
 
Table 10: The Result of the statistical calculation of pharmacokinetics parameter of the test tablet “X” and Reference tablet “R” 
The parameter of pharmacokinetics Ratio of generic to reference  90% CI ratio 
AUC 106.86% t 99.13–120.02% 
AUC 106.90% ∞ 98.87–119.80 % 
C 110.17% max 97.96–129.48 % 
Note: CI was a confidence interval 
Lukitaningsih 




Geometric Average Ratio (AUC)T/(AUC)R = 1.00 with 90% CI = 
80.00-125.00% 
Geometric Average Ratio (Cmax)T/(Cmax)R
CONCLUSION 
 = 1.00 with 90% CI = 
75.00-130.00% 
Based on the calculation result in table 10, it can be concluded that 
those rifampicin tablets met bioequivalence criteria.  
The studied method was successfully applied in the bioequivalence 
study of rifampicin tablet using eight healthy subjects. 
The mean values of AUC0-12 were 29.16±4.05 µg*h/ml and 
27.20±3.98 µg*h/ml, respectively for generic and reference tablet. 
Meanwhile, the mean values of Cmax and tmax for generic tablet were 
5.808±0.880 µg/ml and 1.25±0.13 h, respectively. In addition, the 
mean values of Cmax and tmax for reference tablet were 5.036±0.545 
µg/ml and 1.31±0.13 h. 
The generic rifampicin tablet “X” was bioequivalent to “Rimactan” 
tablet as a reference tablet, since the geometric average ratios of 
(AUC)T/(AUC)R and (Cmax)T/(Cmax)R
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